|Mr. Pablo Gerardo Legorreta||Founder, Chairman & CEO||49.51M||N/A||1964|
|Mr. Terrance P. Coyne||Exec. VP & CFO||3.9M||N/A||N/A|
|Mr. George Wingate Lloyd||Exec. VP of Investments & Chief Legal Officer||3.9M||N/A||1959|
|Mr. Christopher Hite||Vice Chairman & Exec. VP||4.01M||N/A||1967|
|Dr. Marshall Urist M.D., Ph.D.||Exec. VP and Head of Research & Investments||3.55M||N/A||N/A|
|Mr. Arthur R. McGivern J.D.||Exec. VP of Investments & Gen. Counsel||N/A||N/A||N/A|
|Ms. Kristin Stafford||Sr. VP & Chief Accounting Officer||N/A||N/A||N/A|
|Dr. James Folmar Reddoch Ph.D.||Exec. VP of Investments & Chief Scientific Officer||N/A||N/A||1970|
|Mr. George Grofik C.F.A., CPA||Sr. VP and Head of Investor Relations & Communications||N/A||N/A||N/A|
|Ms. Alessandra Sassun||VP & Head of Human Capital||N/A||N/A||N/A|
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc’s ISS Governance QualityScore as of October 1, 2022 is 5. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 6; Compensation: 5.